Business context and reporting period
The supplied filing is MRI Interventions, Inc.’s Form 10-K for the fiscal year ended December 31, 2013, not a quarterly report. Although the request metadata names Clearpoint Neuro, the registrant identified in the filing is MRI Interventions, Inc. The company develops MRI-guided systems for minimally invasive procedures: ClearPoint for brain procedures, which was commercially available, and ClearTrace for cardiac procedures, which remained in development.
At year-end, 31 ClearPoint systems had been installed (29 in the U.S. and two in Europe). ClearPoint had U.S. FDA 510(k) clearance and European CE marking. ClearTrace had not been submitted for regulatory clearance or approval.
Financial performance and position
| Metric | 2013 | 2012 |
|---|---|---|
| Total revenue | $3.93 million | $5.06 million |
| Product revenue | $2.91 million | $1.17 million |
| Operating loss | $7.47 million | $3.13 million |
| Net loss | $7.09 million | $5.88 million |
| Net cash used in operations | $7.78 million | $7.43 million |
| Cash and cash equivalents at year-end | $3.52 million | $1.62 million |
- Product and service revenue was $3.28 million, up 92%. ClearPoint disposable sales rose 75% to $1.8 million, principally reflecting more procedures; reusable-component sales rose to $1.1 million from $150,000.
- Total revenue declined 22% because related-party license revenue fell to $650,000 from $3.35 million as recognition of the 2008 Boston Scientific license fee ended in March 2013.
- Cost of product revenue was $1.42 million. Implied product gross margin was approximately 51%, compared with approximately 53% in 2012; this calculation uses product revenue less cost of product revenue.
- Research and development expense increased 18% to $2.92 million; selling, general and administrative expense increased 17% to $7.06 million. The 2012 comparison included an $883,000 reversal of previously accrued R&D obligations.
- Other items included a $1.69 million non-cash gain from revaluing warrant liabilities, a $1.36 million loss on a note modification, and a $477,000 gain from negotiated reductions in payables. Net interest expense fell to $475,000 from $2.59 million, partly because 2012 included write-offs of debt discounts and financing costs.
- Total assets were $7.87 million, total liabilities $14.71 million, and stockholders’ deficit $6.83 million at December 31, 2013. Current liabilities of $10.09 million exceeded current assets of $5.94 million. The filing does not provide a simple debt-to-equity measure that would be meaningful given the deficit.
Changes, outlook, risks and unusual items
- Cash from financing was $9.85 million, primarily from a January 2013 equity placement. The company reported a cumulative deficit of $72.8 million and said operating losses were expected to continue through at least 2014.
- Management expected 2014 ClearPoint revenue to increase following expansion of the sales and clinical-support team. It estimated that year-end cash, proceeds from a March 2014 financing, and expected product-sale cash would fund anticipated needs through at least March 2015; this is a forward-looking estimate, not a guarantee.
- In March 2014, after year-end, Boston Scientific acquired certain intellectual property in exchange for cancellation of $4.34 million of related-party notes. The company also raised $3.625 million gross through five-year, 12% non-convertible secured notes and warrants; it described net proceeds as approximately $3.4 million. The Boston Scientific transaction also eliminated potential future milestone and royalty payments under the amended agreements.
- The February 2014 Siemens agreement replaced the earlier development agreement and provides for development of commercial software for ClearTrace. Management anticipated an initial EU commercial release in Q4 2015, subject to development and regulatory approvals. The filing notes the U.S. ablation catheter may require a PMA.
- Key risks include continued losses and financing needs, uncertain ClearPoint adoption and reimbursement, ClearTrace development and regulatory hurdles, competition, dependence on suppliers and collaborators, and potential dilution from additional capital raising. The filing also describes a pending arbitration in which Summer Street sought $480,000 and warrants for 460,338 shares; the company disputed the claims, and no liability was recorded because the outcome could not be reasonably estimated.
- Management concluded disclosure controls and internal control over financial reporting were effective as of December 31, 2013. The independent auditor gave an unqualified opinion on the financial statements but did not audit internal control effectiveness.
Important facts for investors to verify
- Whether ClearPoint installations and procedure volumes are translating into durable recurring disposable-product revenue and improving margins.
- Whether cash use, 2014 revenue growth, and any cost-containment measures align with management’s stated runway through March 2015.
- The post-March 2014 debt and security position, including the new 12% notes, the Boston Scientific note cancellation, and any remaining secured obligations.
- Progress, costs, regulatory pathway, and timing for ClearTrace, including Siemens deliverables and the stated EU launch target.
- Outcome of the Summer Street arbitration and any resulting cash, warrant, or legal expense exposure.
- Potential dilution: at December 31, 2013, 12.1 million warrants and 7.4 million options were outstanding; subsequent financing also included warrants.